How do you approach frontline patients in follicular lymphoma?
In this video, the group discusses approaching frontline follicular lymphoma patients, including determining patients who are high risk using symptoms and disease extent.
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
How do you approach a patient with POD24 in follicular lymphoma?
In this video, the group discusses managing POD24 follicular lymphoma patients, emphasizing clinical trials and preference for T-cell engaging therapies over chemotherapy and
Lymphoma Roundtable
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
What are the obstacles in using CELLMoDs in DLBCL?
In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a
ASH 2025
News
DOCK1 inhibition in TP53-mutant clonal hematopoiesis
Recorded at the 67th American Society of Hematology Annual Meeting and Exposition, Yang Feng, PhD, discusses her ASH abstract titled (No.631) “Targeting DOCK1
Lymphoma
Indolent B-Cell Lymphomas
News
EC approves tafasitamab combo in relapsed follicular lymphoma
The European Commission approved tafasitamab (Minjuvi) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL) grade
Lymphoma Roundtable
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
News
Video Interviews
What is the 2025 treatment landscape in DLBCL?
“We have gone from having R-CHOP and chemotherapy in the second link to to having an embarrassment of riches, basically a wealth of
ASH 2025
Leukemia
Acute Myeloid Leukemia
Dr. Gruenbaum, of Blood Cancer United, discusses menin inhibitors in AML
In this SOHO Insider interview from the American Society of Hematology Annual Meeting & Exposition, Lore Gruenbaum, PhD, chief scientific officer at Blood
Multiple Myeloma
News
FDA selects teclistamab MajesTEC-3 sBLA for National Priority Voucher
The United States Food and Drug Administration selected the supplemental Biologics License Application for teclistamab (TECVAYLI) plus daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) to
Leukemia
Lymphoma
Multiple Myeloma
News
Society Updates
SOHO Insider announces new Community Oncology Brown Bag Series
LOS ANGELES—SOHO Insider, the official media platform of the Society of Hematologic Oncology (SOHO) has announced the launch of its Virtual Community Oncology
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA grants priority review to nivolumab with AVD in untreated advanced cHL
The FDA has granted priority review nivolumab in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric patients who are 12